Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1.
Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1.
复制标题
对重组 BPI 和天蚕素 P1 敏感的多粘菌素 B 耐药鲍曼不动杆菌临床分离株。
DOI：
10.1128/aac.45.3.994-995.2001
复制
发表时间：
2001
影响因子：
4.9
通讯作者：
Weiss,J
中科院分区：
文献类型：
--
作者：
Urban,C;Mariano,N;Rahal,JJ;Tay,E;Ponio,C;Koprivnjak,T;Weiss,J
许多鲍曼不动杆菌菌株通过内在和外在机制对多种临床可用的抗菌剂产生耐药性（4，15）。一些研究者已经证实了多药耐药的A。引起医院感染的鲍曼不动杆菌，并且已经证明亚胺培南、舒巴坦和多粘菌素的体外和体内活性（2，9，11，14，16）。对抗菌药物（包括舒巴坦和碳青霉烯类）的耐药性增加，促使多粘菌素B和粘菌素作为治疗药物使用，在过去几年中，多粘菌素用于治疗感染多重耐药革兰氏阴性菌（包括不动杆菌）的患者的频率增加（9，14，16）。尽管临床和微生物学文献表明，A.鲍曼不动杆菌尽管对所有其它抗菌剂具有抗性，但仍保持对多粘菌素的敏感性（2，15），我们记录了分离出的鲍曼不动杆菌多粘菌素B抗性菌株。鲍曼不动杆菌，该患者接受多粘菌素B治疗多药耐药、多粘菌素敏感的鲍曼不动杆菌菌株。鲍曼不动杆菌。多粘菌素抗性菌株（L1）的最小抑制浓度为48 μ g/ml（多粘菌素B）和128 μ g/ml（粘菌素），如通过E-test方法（AB Biodisk North America Inc.，皮斯卡特维，新泽西州）。更重要的是，我们发现该菌株在体外对rBPI 21（Neuprex; XOMA Corporation，Berkeley，CA）敏感。（由S提供）卡罗尔），人杀菌/通透性增加蛋白N-末端结构域的重组形式（表1）。该分离物也对天蚕素P1（Sigma，St. Louis，MO）敏感，一种来自猪肠的抗菌肽（3）。rBPI 21和天蚕素P1的抗菌作用在Mueller-Hinton肉汤的常规MIC和最小杀菌浓度（MBC）测定以及营养肉汤的杀菌测定中均表现出来。在后一种类型的测定中，rBPI 21的抗菌效力，而不是天蚕素
Many strains of Acinetobacter baumannii have become resistant to a variety of clinically available antibacterial agents by both intrinsic and extrinsic mechanisms (4, 15). Several investigators have documented multidrug-resistant A. baumannii causing nosocomial infections and have demonstrated the in vitro and in vivo activities of imipenem, sulbactam, and the polymyxins (2, 9, 11, 14, 16). Increasing resistance to antibacterials, including sulbactam and the carbapenems, has prompted the use of polymyxin B and colistin as therapeutic agents, and within the last several years, the polymyxins have been used with increasing frequency to treat patients infected with multidrug-resistant, gram-negative bacteria, including Acinetobacter (9, 14, 16). Although the literature, both clinical and microbiological, has shown that A. baumannii has retained susceptibility to the polymyxins despite resistance to all other antibacterial agents (2, 15), we document the isolation of a polymyxin B-resistant strain of A. baumannii from a patient who was given polymyxin B for treatment of a multidrugresistant, polymyxin-susceptible strain of A. baumannii. The minimal inhibitory concentrations for the polymyxin-resistant strain (L1) were 48 g/ml (polymyxin B) and 128 g/ml (colistin) as determined by E-test methodology (AB Biodisk North America Inc., Piscataway, NJ). More importantly, we have found that this strain is susceptible in vitro to rBPI21 (Neuprex; XOMA Corporation, Berkeley, Calif.)(provided by S. Carroll), a recombinant form of the N-terminal domain of the human bactericidal/permeability-increasing protein (Table 1). This isolate was also susceptible to cecropin P1 (Sigma, St. Louis, Mo.), an antibacterial peptide from pig intestine (3). The antibacterial effects of rBPI21 and cecropin P1 were manifest both in conventional MIC and minimal bactericidal concentration (MBC) assays with Mueller-Hinton broth and in bactericidal assays with nutrient broth. In the later type of assay, the antibacterial potency of rBPI21, but not of cecropin